Piper Sandler analyst David Amsellem reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $30.00. The company’s shares closed last Friday at ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the “Investors ...

Financial giants have made a conspicuous bearish move on Teva Pharmaceutical Indus. Our analysis of options history for Teva Pharmaceutical Indus TEVA revealed 8 unusual trades. Delving into the ...

Dr. Jeremy Levin, former CEO of Teva Pharmaceuticals and a prominent figure in the global biotech industry. (photo credit: Ovid) Dr. Jeremy Levin, former CEO of Teva Pharmaceuticals and a ...

Deep-pocketed investors have adopted a bullish approach towards Teva Pharmaceutical Indus TEVA, and it's something market players shouldn't ignore. Our tracking of public options records at ...